MSH|^~\&|PTH|RCH|||201911281134||ORU^R01|4116210|D|2.3|||AL|NE PID|1||RC00006059|RC6052|LABTEST^ALASKA^ROLL||19900918|F||||||||||RC000066/17|9876521172 PV1|1|I OBR|1|3259|00002366^17SS-290^PTH^17SS-290^3259||||20171025||||||LABTEST|201710251050|S^SURGICAL SPECIMEN^SURGICAL|||||17SS-290||201911281134|||SOUT OBX|1|TX|Pathology Lab: Surrey Memorial Hospital OBX|2|TX|Phone: (604)588-3384 Fax: (604)585-5562 OBX|3|TX| OBX|4|TX|Specimen Number: 17SS-290 OBX|5|TX| OBX|6|TX|DIAGNOSES OBX|7|TX|test OBX|8|TX| OBX|9|TX|SYNOPTIC REPORT OBX|10|TX|-------- Ewing Sarcoma Biopsy, 1 -------- OBX|11|TX| OBX|12|TX|SPECIMEN COMMENT OBX|13|TX| Pertains To: test OBX|14|TX| OBX|15|TX|SPECIMEN OBX|16|TX| Procedure: Core needle biopsy OBX|17|TX| OBX|18|TX|TUMOUR OBX|19|TX| Tumour Site: Osseous OBX|20|TX| Osseous: Short bones of upper limb and associated OBX|21|TX| joints - test OBX|22|TX| Lymph-Vascular Invasion: Not identified OBX|23|TX| OBX|24|TX|ANCILLARY STUDIES OBX|25|TX| Best Tumour Block: test OBX|26|TX| Immunohistochemistry: test OBX|27|TX| Cytogenetics Findings: EWSR1 rearrangement present OBX|28|TX| EWSR1 Rearrangement: Fusion partner not known OBX|29|TX| Method: Reverse transcriptase polymerase chain OBX|30|TX| reaction (RT-PCR) OBX|31|TX| OBX|32|TX|ADDITIONAL PATHOLOGIC FINDINGS OBX|33|TX| test OBX|34|TX| OBX|35|TX|COMMENT(S) OBX|36|TX| test OBX|37|TX| OBX|38|TX|Based CAP eCC February 2019 OBX|39|TX|---------- End of Synoptic Report ---------- OBX|40|TX|-------- Ewing Sarcoma Resection, 2 -------- OBX|41|TX| OBX|42|TX|SPECIMEN COMMENT OBX|43|TX| Pertains To: test OBX|44|TX| OBX|45|TX|CLINICAL OBX|46|TX| Preresection Treatment: Radiation therapy performed OBX|47|TX| OBX|48|TX|SPECIMEN OBX|49|TX| Procedure: Resection OBX|50|TX| OBX|51|TX|TUMOUR OBX|52|TX| Tumour Site: Osseous OBX|53|TX| Osseous: Bone of limb, NOS - test OBX|54|TX| Tumour Size: 4 x 2 x 2 cm OBX|55|TX| Primary Tumour Location: Diaphysis OBX|56|TX| Lymph-Vascular Invasion: Present OBX|57|TX| Treatment Effect: Necrosis not identified OBX|58|TX| OBX|59|TX|MARGINS OBX|60|TX| Margins negative for tumour OBX|61|TX| Distance of Tumour From Closest Bone OBX|62|TX| Margin: 4 cm OBX|63|TX| Distance of Tumour From Closest Soft OBX|64|TX| Tissue Margin: 4 cm OBX|65|TX| Distance of Tumour From Closest OBX|66|TX| Other (e.g. parenchymal) Margin: 3 cm OBX|67|TX| OBX|68|TX|LYMPH NODES, REGIONAL OBX|69|TX| Number of Lymph Nodes Examined: 4 OBX|70|TX| Number of Lymph Nodes Involved: 2 OBX|71|TX| OBX|72|TX|PATHOLOGIC STAGE OBX|73|TX| Distant Metastasis (pM): Present OBX|74|TX| Specify site(s), if known: test OBX|75|TX| OBX|76|TX|ADDITIONAL PATHOLOGIC FINDINGS OBX|77|TX| test OBX|78|TX| OBX|79|TX|ANCILLARY STUDIES OBX|80|TX| Best Tumour Block: test OBX|81|TX| Immunohistochemistry: test OBX|82|TX| Cytogenetic Findings: EWSR1 rearrangement present OBX|83|TX| Fusion Partner Detection: Fusion partner known OBX|84|TX| Fusion Partner Genes: ERG OBX|85|TX| OBX|86|TX|COMMENT(S) OBX|87|TX| test OBX|88|TX| OBX|89|TX|Based on AJCC/UICC TNM, 7th edition; CAP eCC August 2016 OBX|90|TX|---------- End of Synoptic Report ---------- OBX|91|TX|-------- Ewing Sarcoma Resection, 3 -------- OBX|92|TX| OBX|93|TX|CLINICAL OBX|94|TX| Preresection Treatment: Radiation therapy performed OBX|95|TX| OBX|96|TX|SPECIMEN OBX|97|TX| Procedure: Resection OBX|98|TX| OBX|99|TX|TUMOUR OBX|100|TX| Tumour Site: Extraosseous OBX|101|TX| Extraosseous: Peritoneum and / or retroperitoneum OBX|102|TX| Primary Tumour Site (peritoneum Peritoneum, including omentum and mesentery OBX|103|TX| and / or retroperitoneum): - - test OBX|104|TX| Tumour Size: 8 x 5 x 4 cm OBX|105|TX| Primary Tumour Location: Medullary cavity OBX|106|TX| Lymph-Vascular Invasion: Present OBX|107|TX| Treatment Effect: Necrosis present OBX|108|TX| Tumour necrosis: 20 % OBX|109|TX| OBX|110|TX|MARGINS OBX|111|TX| Margins negative for tumour OBX|112|TX| Distance of Tumour From Closest Bone OBX|113|TX| Margin: 4 cm OBX|114|TX| Distance of Tumour From Closest Soft OBX|115|TX| Tissue Margin: 3 cm OBX|116|TX| Distance of Tumour From Closest OBX|117|TX| Other (e.g. parenchymal) Margin: 4 cm OBX|118|TX| Comment: test OBX|119|TX| OBX|120|TX|LYMPH NODES, REGIONAL OBX|121|TX| Number of Lymph Nodes Examined: 3 OBX|122|TX| Number of Lymph Nodes Involved: 2 OBX|123|TX| OBX|124|TX|PATHOLOGIC STAGE OBX|125|TX| Distant Metastasis (pM): Present OBX|126|TX| Site(s): test OBX|127|TX| OBX|128|TX|ADDITIONAL PATHOLOGIC FINDINGS OBX|129|TX| testing testing OBX|130|TX| OBX|131|TX|ANCILLARY STUDIES OBX|132|TX| Best Tumour Block: test OBX|133|TX| Immunohistochemistry: test OBX|134|TX| Cytogenetic Findings: EWSR1 rearrangement present OBX|135|TX| Fusion Partner Detection: Fusion partner known OBX|136|TX| Fusion Partner Genes: ERG OBX|137|TX| OBX|138|TX|COMMENT(S) OBX|139|TX| test OBX|140|TX| OBX|141|TX|Based CAP eCC February 2019 OBX|142|TX|---------- End of Synoptic Report ---------- OBX|143|TX|-------- Rhabdomyosarcoma, Undifferentiated sarcoma, Ectomesenchymoma, 4 -------- OBX|144|TX| OBX|145|TX|SPECIMEN COMMENT OBX|146|TX| Pertains To: test OBX|147|TX| OBX|148|TX|SPECIMEN OBX|149|TX| Procedure: Marginal resection OBX|150|TX| Preoperative Treatment: Chemotherapy given OBX|151|TX| OBX|152|TX|TUMOUR OBX|153|TX| Tumour Site: Bladder / prostate OBX|154|TX| Histologic Type: Alveolar OBX|155|TX| Tumour Size: 5 cm OBX|156|TX| Anaplasia: Focal (single or few scattered anaplastic OBX|157|TX| cells) OBX|158|TX| OBX|159|TX|MARGINS OBX|160|TX| Margins: Negative for tumour OBX|161|TX| Distance of Tumour From Closest OBX|162|TX| Margin: 5 cm OBX|163|TX| Margin: test OBX|164|TX| OBX|165|TX|LYMPH NODES, REGIONAL OBX|166|TX| Number of Lymph Nodes Examined: 5 OBX|167|TX| Number of Lymph Nodes Involved: 4 OBX|168|TX| Distant Metastasis: Distant metastasis present OBX|169|TX| Site(s): test OBX|170|TX| OBX|171|TX|PATHOLOGIC STAGE OBX|172|TX| The Intergroup Rhabdomyosarcoma Any size primary tumour, with or without OBX|173|TX| Study Postsurgical Clinical Grouping regional lymph node involvement, with OBX|174|TX| System: distant metastases, without respect to OBX|175|TX| surgical approach to primary tumour. OBX|176|TX| Modified Site, Size, Metastasis OBX|177|TX| Staging for Rhabdomyosarcoma: OBX|178|TX| Stage IV: Distant metastases present OBX|179|TX| OBX|180|TX|ANCILLARY STUDIES OBX|181|TX| Best Tumour Block: test OBX|182|TX| Fusion Status: FOXO1 rearrangement present OBX|183|TX| FOXO1 Rearrangement: Amplification status OBX|184|TX| Method: FISH OBX|185|TX| OBX|186|TX|COMMENT(S) OBX|187|TX| test OBX|188|TX| OBX|189|TX|Based on The Intergroup Rhabdomyosarcoma Study Postsurgical Clinical Grouping System OBX|190|TX|---------- End of Synoptic Report ---------- OBX|191|TX| OBX|192|TX|SPECIMEN SUBMITTED OBX|193|TX|TESTING OBX|194|TX| OBX|195|TX|CLINICAL INFORMATION OBX|196|TX|TESTING OBX|197|TX| OBX|198|TX|GROSS DESCRIPTION OBX|199|TX|TESTING OBX|200|TX| OBX|201|TX|MICROSCOPIC DESCRIPTION OBX|202|TX|TESTING OBX|203|TX| ____________________________________ OBX|204|TX| Teresa Chow OBX|205|TX| Electronically signed: 28/Nov/2019 OBX|206|TX| OBX|207|TX|-------------------------------------------------------------------------------------------- OBX|208|TX| OBX|209|TX|